Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2

Chaolin Zhang,^{1,2,5} Zuo Zhang,^{1,5} John Castle,³ Shuying Sun,^{1,4} Jason Johnson,³ Adrian R. Krainer,^{1,6} and Michael Q. Zhang^{1,7}

¹Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; ²Department of Biomedical Engineering, The State University of New York at Stony Brook, Stony Brook, New York 11794, USA; ³Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co., Seattle, Washington 98109, USA; ⁴Department of Molecular and Cellular Biology, The State University of New York at Stony Brook, Stony Brook, New York 11794, USA

The precise regulation of many alternative splicing (AS) events by specific splicing factors is essential to determine tissue types and developmental stages. However, the molecular basis of tissue-specific AS regulation and the properties of splicing regulatory networks (SRNs) are poorly understood. Here we comprehensively predict the targets of the brain- and muscle-specific splicing factor Fox-1 (A2BP1) and its paralog Fox-2 (RBM9) and systematically define the corresponding SRNs genome-wide. Fox-1/2 are conserved from worm to human, and specifically recognize the RNA element UGCAUG. We integrate Fox-1/2-binding specificity with phylogenetic conservation, splicing microarray data, and additional computational and experimental characterization. We predict thousands of Fox-1/2 targets with conserved binding sites, at a false discovery rate (FDR) of ~24%, including many validated experimentally, suggesting a surprisingly extensive SRN. The preferred position of the binding sites differs according to AS pattern, and determines either activation or repression of exon recognition by Fox-1/2. Many predicted targets are important for neuromuscular functions, and have been implicated in several genetic diseases. We also identified instances of binding site creation or loss in different vertebrate lineages and human populations, which likely reflect fine-tuning of gene expression regulation during evolution.

[**Keywords:** Tissue-specific alternative splicing; splicing regulatory network; Fox-1/A2BP1; Fox-2/RBM9; UGCAUG; comparative genomics]

Supplemental material is available at <http://www.genesdev.org>.

Received June 6, 1007; revised version accepted July 28, 2008.

The sequencing of complete genomes revealed that complex metazoans, including mammals, have only slightly more genes than unicellular yeast (International Human Genome Sequencing Consortium 2001). Organismal complexity must have resulted largely from mechanisms for diversifying the expression products, and the temporal and spatial patterns, from a limited set of genes. It is crucial to understand how gene expression is orchestrated to determine developmental stages, specify cell types, and respond to external stimuli (Maniatis and Reed 2002). Alternative splicing (AS), the process for removing introns from pre-mRNA transcripts and joining exons in different combinations, is an essential step of post-transcriptional regulation (Cartegni et al. 2002;

Black 2003). In mammals, more than two-thirds of genes are alternatively spliced (Johnson et al. 2003). The choice of exons and splice sites is largely determined by many RNA-binding proteins, or splicing factors, which interact with *cis*-regulatory elements to activate or repress particular splicing events.

Many splicing factors have restricted and dynamic expression patterns, and play important roles in tissue-specific or developmentally regulated splicing of particular transcripts. However, the mechanisms and impact of these AS events remain poorly understood. A well-studied example is Sxl, Tra, Tra-2, and several other splicing factors in *Drosophila*, which regulate a cascade of AS events to control sex determination (Lopez 1998). In mammals, tissue-specific splicing factors include Nova-1/2, PTB/nPTB, Fox-1/2, Muscleblind-like (MBNL) and CELF family proteins, Hu proteins, TIA1/TIAR, and probably many more yet to be characterized (for reviews, see Li et al. 2007; David and Manley 2008). The identification of the RNA targets of these factors is critical for

⁵These authors contributed equally to this work.
Corresponding authors.

⁶E-MAIL krainer@cshl.edu; FAX (516) 367-8453.

⁷E-MAIL mzhang@cshl.edu; FAX (516) 367-8461.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1703108>.

understanding the splicing regulatory networks (SRNs), but remains challenging; in most cases, only a handful of targets have been determined experimentally. Recently, the development of high-throughput technologies that monitor mRNA isoform abundances and protein–RNA interactions, including splicing microarrays (Johnson et al. 2003; Ule et al. 2005b; Sugnet et al. 2006; Boutz et al. 2007b), RNP immunoprecipitation-microarray (RIP-Chip) (Keene et al. 2006), and ultraviolet cross-linking and immunoprecipitation (CLIP) assays (Ule et al. 2005a), provided new opportunities to identify *in vivo* RNA targets and characterize SRNs genome-wide (for reviews, see Blencowe 2006; Moore and Silver 2008). This has been demonstrated already in studies of Nova-1/2 targets, which revealed important functions of coregulated targets in the neuronal synapse and in axon guidance, as well as mechanisms by which Nova-1/2 activate or repress exon inclusion, depending on the locations of their binding sites (Ule et al. 2006). Other studies described subsets of exons with splicing patterns characteristic of particular tissues, or associated with responses to certain stimuli; these exons sometimes show enrichment of RNA sequence motifs and Gene Ontology (GO) terms, suggesting coordinated splicing regulation that could be important for cellular functions (Sugnet et al. 2006; Das et al. 2007; Fagnani et al. 2007; Ip et al. 2007; McKee et al. 2007). However, more detailed studies are required to identify individual targets for particular splicing factors.

Computational target prediction for specific splicing factors is difficult, largely due to the small size and degeneracy of splicing-factor-binding motifs. An exception to this degeneracy is the hexanucleotide UGCAUG, which is an important intronic element for the splicing of several exons (Huh and Hynes 1994; Kawamoto 1996; Lim and Sharp 1998). A computational study further suggested that this element is enriched in the introns downstream from a set of neuron-specific exons (Brudno et al. 2001). Importantly, the zebrafish and mammalian homologs of *Caenorhabditis elegans* fox-1 were identified as recognizing the (U)GCAUG element (Jin et al. 2003; Ponthier et al. 2006). In *C. elegans*, the fox-1 gene is critical in the sex determination pathway for X-chromosome dosage compensation (Meyer 2000). In mammals, Fox-1 (also known as A2BP1) encodes an RNA-binding protein initially identified as an interacting partner of ataxin-2, and has at least one paralog, Fox-2 (also known as RBM9 or Fxh) (Nakahata and Kawamoto 2005). Human Fox-1 and Fox-2 share very high sequence homology—100% identity in the RRM domain—and bind to the same RNA element (Supplemental Fig. S1; Kiehl et al. 2001; Jin et al. 2003; Auweter et al. 2006; Ponthier et al. 2006). Both proteins are exclusively or preferentially expressed in brain, heart, and skeletal muscle. In addition, mutation or abnormal expression of Fox-1 has been found in patients with several genetic diseases, including epilepsy, mental retardation (Bhalla et al. 2004), autism (The Autism Genome Project Consortium 2007; Martin et al. 2007; Sebat et al. 2007), and heart disease (Kaynak et al. 2003). Fox-2 was also implicated in hormone signaling, as a corepressor of tamoxifen activation of the

estrogen receptor (Norris et al. 2002). Therefore, Fox-1/2 are likely essential regulators for tissue-specific splicing, and systematic analysis of their targets may provide important insights into the mechanisms of tissue-specific splicing regulation, the characteristics of SRNs, and their physiological roles.

In this study, we define and characterize the SRNs of Fox-1/2. We combined computational predictions from comparative genomics analysis, with experimental validation and characterization. Strikingly, our analysis revealed thousands of potential Fox-1/2 targets with binding sites highly conserved across vertebrate species. Fox-1/2 can either activate or repress splicing, depending on the locations of their binding sites, and also contribute to more complex splicing patterns. Many of the predicted targets play important roles in neuromuscular functions and disorders. We also discuss the evolution of Fox-1/2-binding sites across different vertebrate lineages and among different human populations, and the potential phenotypic implications.

Results

Comparative genomics analysis defines extensive Fox-1/2 SRNs with high specificity

Several previous studies found the enrichment of the UGCAUG element in conserved intronic sequences flanking brain-specific exons or conserved alternative exons (Brudno et al. 2001; Minovitsky et al. 2005; Sugnet et al. 2006; Voelker and Berglund 2007; Yeo et al. 2007), but it was unclear if the sequence specificity and conservation are sufficient to predict Fox-1/2 targets. To characterize global features of SRNs, we sought to develop an effective method for genome-wide Fox-1/2 target prediction. We searched all human internal exons, and 200 nucleotides (nt) of upstream and downstream intronic flanking (UIF and DIF) regions for conserved UGCAUG elements, taking advantage of 28 sequenced vertebrate genomes (Miller et al. 2007). The inclusion of many species for comparison, in contrast to previous studies (Minovitsky et al. 2005; Voelker and Berglund 2007; Yeo et al. 2007), was justified by their power in reducing the false-positive rate in pairwise species analysis (Supplemental Fig. S2; see also Supplemental Material). To account for the different levels of divergence among the vertebrate genomes, we adapted a branch length score (BLS) method (Stark et al. 2007) to measure the conservation level of each UGCAUG element, as summarized in Supplemental Figure S3. Several examples of elements with different levels of conservation, along with their BLS scores, are shown below (see Fig. 6C, below). The false discovery rate (FDR) associated with each BLS score was then determined using shuffled random motifs as controls.

To determine appropriate BLS thresholds, we initially studied cassette exons, the most frequent form of AS in mammals (Thanaraj et al. 2004). The conserved fraction of Fox-1/2 sites in UIF and DIF sequences is higher than that of random sites for the whole range of BLS thresholds (Fig. 1A, left and right panels), which confirms and

Figure 1. Comparative analysis accurately predicts Fox-1/2 targets. (A, left axis) The number of conserved Fox-1/2-binding sites (blue) and random-motif sites (gray) in UIF (left), exonic (middle), and DIF (right) sequences of cassette exons, using varying thresholds of BLSs. Error bars represent standard error of the mean. (Right axis) The corresponding FDR of prediction is shown in red. The thresholds used in the paper (0.22 for UIF and DIF sites and 0.8 for exonic sites) are indicated by arrowheads. (B) Proportions of different types of splicing patterns for predicted Fox-1/2 targets (left) and all internal exons (right). (C–G) Distribution of conserved Fox-1/2-binding sites in different regions for cassette exons (C), mutually-exclusive exons (D), alternative 5' splice sites (E), and 3' splice sites (F), and constitutive exons (G). In each panel, the splicing pattern is shown schematically above the histogram. The distribution of conserved Fox-1/2 sites is color-coded as in B. The distribution of conserved random-motif sites is shown in gray for comparison.

extends previous observations (Brudno et al. 2001; Minovitsky et al. 2005; Voelker and Berglund 2007; Yeo et al. 2007). Importantly, the comparative analysis of many vertebrate species makes it possible to achieve very low FDRs. Excess Fox-1/2 site conservation in the exons was observed only when we applied very stringent BLS thresholds, which correspond to conservation beyond mammals (Fig. 1A, middle panel; Supplemental Fig. S2B). As a trade-off between sensitivity and specificity of target prediction, we required a BLS threshold of 0.22 for UIF and DIF sites, corresponding to an FDR of 0.24 and 0.15, respectively; for exonic sites, a BLS threshold of 0.8 was required to achieve comparable specificity (FDR = 0.24) (Fig. 1A, indicated by arrowheads).

We then applied these thresholds to all human internal exons, and predicted 1706 target exons (1457 after overlapping exon variants were merged) from 1103 genes, with at least one conserved Fox-1/2-binding site (FDR = 24%) (Supplemental Table S1). This includes 192 exons with two or more sites in the same or different regions (FDR = 0.03). Compared with 10 known Fox-1/2 targets determined by previous studies, our predictions successfully included six; the other four were missed because their binding sites are too far away from the exons or do not reach the conservation level we required, or the exon was not included in our database (Supplemental Table S2).

The predicted Fox-1/2 target exons have a number of characteristics similar to those of known regulated tissue-specific exons. Overall, 757 exons are alternatively spliced (Fig. 1B, left panel), and this proportion is significantly higher than the overall fraction of AS exons (Fig. 1B, right panel) in the human genome (44.4% vs. 25.7%, $P = 5 \times 10^{-63}$). Among predicted targets with AS are 544 cassette exons (including some with multiple types of AS), which is a significant over-representation, compared with the expected proportion estimated from all AS exons (48.6% vs. 29.6%, $P = 1.4 \times 10^{-27}$). A more stringent comparison to exons with conserved random motifs gave qualitatively similar results (data not shown). Importantly, the AS exons predicted as Fox-1/2 targets, and cassette exons in particular, have more conserved AS patterns in mouse/rat (50.7% vs. 10%–20%) (Blencowe 2006), smaller exon sizes (75 nt vs. 110 nt median), and a higher tendency to preserve the reading frame (67.5% vs. 42%), compared with all cassette exons, consistent with previous observations from tissue-specific exons (Blencowe 2006; Sugnet et al. 2006; Fagnani et al. 2007). We expect that the proportion of AS exons we observed is an underestimate, because many AS exons with low EST coverage may be misclassified as constitutive exons. Among the exons currently without evidence of AS, 83 (8.7%) have mouse and/or rat orthologous exons associated with AS events, and 176 (18.5%) are predicted as alternative conserved exons (ACEs) (Yeo et al. 2005). In summary, comparative analysis of multiple genomes provides an effective way to predict functional Fox-1/2 targets.

Different types of AS events correlate with distinct patterns of Fox-1/2 motif distribution

Since all typical types of alternative exons and splice sites are present in our predicted Fox-1/2 targets, we examined the distribution of Fox-1/2-binding sites separately for each type. We found that the positional preference of Fox-1/2-binding sites differs among different types of AS events. For cassette exons, conserved Fox-1/2-binding sites are 1.75-fold more enriched in the DIF vs. the UIF region (Fig. 1C), in contrast to the approximately equal enrichment for conserved random sites ($P = 1.8 \times 10^{-8}$). No preference for the UIF and DIF regions was observed in the case of mutually exclusive or constitutive exons (Fig. 1D,G). Interestingly, for exons

region vs. the UIF region, DIF sites were generally associated with inclusion of the upstream exon (Fig. 2C), confirming and extending several previous studies (Jin et al. 2003; Underwood et al. 2005; Sugnet et al. 2006; Das et al. 2007).

We further examined four exon clusters with different combinations of splicing patterns in brain and heart/skeletal muscle tissues: (1) exons specifically included in both brain and heart/muscle (B[+]*M*[+]); (2) exons specifically included only in brain (B[+]*M*[-]); (3) exons specifically skipped in brain and muscle/heart (B[-]*M*[-]); and (4) exons specifically skipped in brain (B[-]*M*[+]) (Fig. 2A). We reasoned that exons mainly regulated by Fox-1/2 should have consistent splicing patterns in brain and heart/muscle, because Fox-1 and Fox-2 have high expression in these tissues. Therefore, focusing on the B[+]*M*[+] and B[-]*M*[-] clusters should minimize complications due to other factors, and help to infer the rules for Fox-1/2-mediated splicing, as influenced by the locations of the binding sites. Indeed, these two clusters have very distinct spatial distributions of putative Fox-1/2-binding sites (Fig. 2D,F). The B[+]*M*[+] cluster (Fig. 2D) shows a very strong tendency for the sites being located in the DIF region, rather than the UIF region (sixfold enrichment, $P = 0.007$, compared with random motif sites) (Fig. 2H). This bias suggests that downstream Fox-1/2-binding sites are potent splicing enhancers in general. In contrast, for the B[-]*M*[-] cluster, we observed an opposite pattern of Fox-1/2-binding site distribution, with a ninefold enrichment in the UIF region (Fig. 2F) ($P = 0.0007$, compared with random motif sites). This in turn strongly suggests that upstream binding sites repress exon inclusion. Therefore, our analysis provides strong evidence that the different effects of Fox-1/2 in splicing regulation generally depend on the locations of the binding sites.

The other two clusters are also intriguing and indicative of combinatorial regulation. In addition to Fox-1/2, other splicing factors may play an important role in tissue-specific splicing of these exons. For example, for the exons in the B[-]*M*[+] cluster (Fig. 2G), Fox-1/2-binding sites are significantly enriched in the DIF region ($P = 4 \times 10^{-5}$), to an extent similar to that observed in the B[+]*M*[+] cluster. However, these exons show very low inclusion in brain. This pattern could be explained by brain-specific repressors that counteract the enhancing effects of Fox-1/2, or by muscle/heart-specific coactivators that promote exon inclusion together with Fox-1/2.

To confirm the splicing patterns observed from the splicing microarrays, we performed semiquantitative RT-PCR assays of several endogenous transcripts. In all six cases we tested, cassette exons with conserved downstream intronic sites (*FMNL3*, *PTBP2*, and *UAP1*) showed brain- and/or muscle/heart-specific exon inclusion, whereas those with only conserved upstream intronic sites (*PB1*, two exons from *MBNL1*) showed brain- and/or muscle/heart-specific skipping (Fig. 3). Of particular interest is the *UAP1* exon, which was included in muscle and heart, but predominantly skipped in brain, despite the presence of multiple downstream binding

Figure 3. RT-PCR analysis of predicted cassette exons shows brain- and/or heart/muscle-specific splicing. Exon inclusion level was measured in six human tissues by radioactive RT-PCR. In each panel, the quantified exon inclusion level and the number of conserved UIF, exonic, and DIF UGCAUG elements are indicated *above* and *below* the gene symbol, respectively. The size of each PCR product is also indicated.

sites. Different exon-inclusion levels in brain and muscle/heart were also observed for *MBNL1* exons. The splicing patterns observed by RT-PCR are generally consistent with those observed with the splicing microarrays, although a quantitative assessment will require additional experiments. More importantly, the results support the idea that Fox-1/2 alone are not always sufficient to determine the tissue-specific splicing pattern of target genes.

Overexpression and knockdown of Fox-1/2 alter the splicing of predicted Fox-1/2 targets depending on the presence of the UGCAUG element

To validate the predicted targets and the position-dependent effect of Fox-1/2-binding sites more directly, we next tested the splicing of endogenous pre-mRNAs in the presence or absence of Fox-1/2 proteins. We first examined Fox-1/2 expression in several cell lines by Western blotting. In all the cell lines we tested, including a few neuronal cell lines, we found variable levels of Fox-2 protein, but no Fox-1 (data not shown). Because RNAi is very effective in HeLa cells, which express a low but readily detectable level of Fox-2, we used this cell line to test for AS of our predicted targets. For comparison, we generated HeLa cell derivatives expressing different combinations of Fox-1/2—i.e., neither Fox-1 nor Fox-2, Fox-1 only, Fox-2 only, and both Fox-1 and Fox-2—by stable transduction of shRNAs targeting Fox-1 or Fox-2, and/or Fox-1/2 cDNAs in retroviral vectors. Initial examination using several predicted targets showed that expression of either Fox-1 or Fox-2 robustly changed splicing of target exons, compared with the cells without Fox-1/2, in a way similar to that in cells expressing both

Figure 4. RT-PCR analysis after stable Fox-1/2 overexpression and knockdown in HeLa cells validates predicted targets. (A) Schematic representation of experimental validation in control or transduced HeLa cells. Control HeLa cells express Fox-2 but not Fox-1. Two other transductant pools without Fox-1/2 expression or with only Fox-1 expression were generated by stable retroviral transduction with an shRNA against Fox-2 (shFox-2), or with a combination of shRNA against Fox-2 and stable transfection of Fox-1 cDNA (shFox-2 + Fox-1). The expression of Fox-1 or Fox-2 was confirmed by Western blotting analysis using antibodies specific for each protein. (Lane 1) HeLa cells with shRNA

knockdown of Fox-2. (Lane 2) untreated HeLa cells. (Lane 3) HeLa cells with shRNA knockdown of Fox-2 and stable transduction of Fox-1 cDNA. (B,C) Radioactive RT-PCR analysis of predicted Fox-1/2 targets with downstream intronic binding sites (B), or with only upstream intronic binding sites (C). All examples are cassette exons. For each exon, the gene symbol is shown *below*, together with the number of conserved Fox-1/2-binding sites in UIF, exonic, and DIF sequences. In each panel, the quantified exon-inclusion level and the number of conserved UIF, exonic, and DIF UGCAUG elements are indicated *above* and *below* the gene symbol, respectively. The size of each PCR product is also labeled. For some of the genes, indicated by an asterisk, the splicing pattern in tissues was also measured by RT-PCR, as shown in Figure 3.

proteins (Supplemental Fig. S4A,B). Therefore, for simplicity, we focused on three derivatives expressing no Fox-1/2 (Fig. 4A, lane 1), Fox-2 only (Fig. 4A, lane 2), and Fox-1 only (Fig. 4A, lane 3) for more extensive validation.

From our list of predicted targets, we chose to test those with binding sites with a wide range of conservation scores, but favored genes involved in gene expression regulation, such as transcription and RNA processing, and with links to genetic diseases. Among 33 tested cassette exons with conserved downstream intronic sites and detectable expression in HeLa cells, 18 (55%) clearly gave a higher level of exon inclusion in the presence of Fox-1 or Fox-2 (Fig. 4B; Supplemental Fig. S5; Supplemental Table S5), whereas the rest did not show a discernible change; none of them gave a reduction in exon inclusion. Among the 22 tested cassette exons with only conserved upstream intronic sites, 13 (59%) showed a clear change of inclusion level when Fox-1 or Fox-2 was expressed (Fig. 4C; Supplemental Fig. S6; Supplemental Table S5). With the exception of *PLD2*, all of these exons (12 of 13) were repressed by Fox-1/2. These results suggest a satisfactory validation rate of 55%–60%, given the fact that we started from pure computational predictions. Consistent with the splicing microarray data, these analyses strongly indicate the enhancer character of downstream intronic sites, and silencer character of upstream intronic sites, that are predictive of Fox-1/2-regulated splicing.

We next tested if Fox-1/2-regulated splicing depends on the presence of UGCAUG element(s). To this end, we generated two minigene constructs: one from the *FMNL3* gene (Fig. 5A) and the other from the *PB1* gene (Fig. 5C). The *FMNL3* minigene comprises the two constitutive exons flanking the cassette exon and both introns (Fig. 5A). Inclusion or skipping of the cassette exon results in the use of different stop codons. In the wild-type minigene, there are four conserved Fox-1/2 sites

downstream from the cassette exon. The exon inclusion level greatly increased when Fox-1 was overexpressed, recapitulating the splicing pattern of the endogenous gene (Fig. 5B, lanes 1,2). In contrast, Fox-1-mediated exon inclusion became much weaker or completely disappeared when two of the sites (Fig. 5B, lanes 3,4 with mutations in sites 1 and 2, lanes 6,7 with mutations in sites 3 and 4) or all four sites (Fig. 5B, lanes 7,8) were mutated.

The *PB1* minigene is a chimeric construct consisting of the *PB1* cassette exon with partial flanking introns (~250 nt from the upstream and downstream introns, respectively) inserted into intron 1 of a human β -globin gene splicing reporter (Fig. 5C). There are three conserved Fox-1/2 sites upstream of the cassette exon. As shown in Figure 5D, overexpression of Fox-1 strongly inhibited inclusion of the cassette exon (lanes 1,2). When we mutated one or more of the UGCAUG sites, the inhibitory effect of Fox-1 was reduced or eliminated (Fig. 5D, lanes 3–10). Therefore, Fox-1/2-mediated AS of both *FMNL3* and *PB1* genes depends on the presence of UGCAUG elements.

Predicted Fox-1/2 targets are enriched in genes with neuromuscular functions

The large number of predicted targets raises the important question of how the Fox-1/2 SRNs are organized to perform cellular functions. To achieve a better understanding of the SRNs, we examined GO terms enriched in the predicted Fox-1/2 target genes, in comparison with a control gene set derived from exons with a similar conservation level (see Materials and Methods). Many Fox-1/2 target genes have neuromuscular functions, which is reflected in top GO terms related to cytoskeleton organization, ion channels, protein phosphorylation, muscle contraction, etc. (Table 1). Some of these GO terms were identified previously from smaller sets of brain/muscle-

Figure 5. Fox-1/2-mediated splicing regulation depends on the UGCAUG elements. (A) Schematic representation of the *FMNL3* minigene, which has four natural copies of putative Fox-1/2-binding sites (labeled 1–4) in DIF sequences. Different use of stop codons due to AS is also indicated by red circles. The conservation pattern of the region is displayed under the diagram. (B) Splicing of the *FMNL3* minigene cassette exon in the wild-type minigene, without or with Fox-1 protein, is shown in lanes 1 and 2, respectively. Lanes 3–8 show the splicing of the mutant minigenes. Mut12 (lanes 3,4) has mutations in sites 1 and 2, and similarly for Mut34 (lanes 5,6) and Mut 1234 (lanes 7,8). The quantified exon inclusion level is indicated. The expression level of Fox-1 was confirmed by Western blotting, as shown at the bottom. (C) Schematic representation of the *PB1* minigene. The conservation pattern of the region is displayed under the diagram. The cassette exon, together with ~250 nt of UIF and DIF sequences, including three natural putative Fox-1/2-binding sites in the UIF region, were inserted into intron 1 of the human β -globin gene. (D) Splicing of the *PB1* minigene. See the legend for B for more details.

specific exons, or exons with UGCAUG elements (Das et al. 2007; Fagnani et al. 2007; Yeo et al. 2007), likewise suggesting similar functions of many predicted targets.

Consistently, disruptions of our predicted Fox-1/2 target genes were previously implicated in neurological, neurodegenerative, and sensory disorders, as well as heart

Table 1. Representative GO functions of predicted Fox-1/2 target genes

GO term	Count	P-value	Fold change	FDR (Benjamini)
Biological process				
Cytoskeleton organization and biogenesis	68	1.1E-11	2.4	3.7E-08
Actin filament-based process	37	6.5E-09	2.9	1.1E-05
Potassium ion transport	31	1.7E-07	2.9	1.1E-04
Metal ion transport	56	2.0E-07	2.1	1.1E-04
Ion transport	91	3.0E-07	1.7	1.4E-04
Cation transport	65	2.2E-06	1.8	9.0E-04
System development	61	2.6E-06	1.9	9.6E-04
Nervous system development	59	8.3E-06	1.8	2.1E-03
Muscle contraction	28	1.8E-05	2.5	4.3E-03
Protein amino acid phosphorylation	70	4.2E-05	1.6	6.9E-03
Cellular component				
Cytoskeleton	123	2.5E-15	2.1	1.5E-12
Actin cytoskeleton	51	1.2E-13	3.2	3.5E-11
Non-membrane-bound organelle	148	7.1E-09	1.6	1.1E-06
Myofibril	15	3.2E-08	5.9	3.9E-06
Synapse	30	9.2E-08	3.0	9.4E-06
Myosin	18	8.0E-07	4.0	7.0E-05
Sarcomere	13	1.0E-06	5.5	6.7E-05
Microtubule-associated complex	24	1.7E-06	3.1	9.7E-05
Striated muscle thick filament	9	9.1E-06	7.1	4.3E-04
A band	9	9.1E-06	7.1	4.3E-04
Post-synaptic membrane	18	8.8E-05	2.9	3.6E-03
Golgi-associated vesicle membrane	9	5.3E-04	4.5	1.9E-02
Molecular function				
Cytoskeletal protein binding	79	4.4E-19	3.0	1.1E-15
Actin binding	55	2.0E-13	3.0	1.6E-10
Motor activity	38	1.4E-12	3.7	8.8E-10
Calmodulin binding	37	2.4E-12	3.8	1.2E-09
Ion channel activity	53	3.0E-07	2.1	1.0E-04
Enzyme binding	35	2.3E-06	2.4	5.6E-04

disease and muscular dystrophy, according to the OMIM database (Supplemental Table S5; McKusick 1998). Therefore, our systematic results support and extend several scattered observations in the literature (Kaynak et al. 2003; Bhalla et al. 2004; The Autism Genome Project Consortium 2007; Martin et al. 2007; Sebat et al. 2007). Interestingly, we found that predicted Fox-1/2 targets are more likely than expected by chance to be disease genes: 157 of 1103 predicted target genes (14.2%) are annotated in the OMIM database as disease genes, compared with a proportion of 7.8% for all genes ($P = 8.3 \times 10^{-14}$), or 10.7% for control genes with a comparable conservation level ($P = 0.0001$) (Supplemental Table S7). This correlation is indicative of the potential pathological impact when conserved tissue-specific SRNs are dysregulated. We also note that the predicted target genes also have many more introns than the control genes (15 vs. eight, median, according to RefSeq transcripts, $P < 2.1 \times 10^{-16}$, Wilcoxon rank sum test). Disease genes tend to be more intron-rich than average, and are thus more susceptible to splicing dysregulation (López-Bigas et al. 2005), which could contribute to the association between Fox-1/2 targets and OMIM phenotypes we observe.

Creation and loss of Fox-1/2-binding sites may contribute to fine-tuning of gene expression

The large number of species included in our comparative analysis makes it possible to study not only the conservation, but also the evolutionary creation and loss of

Fox-1/2-binding sites in specific lineages. Here we mainly analyzed the intronic sites, due to the difficulty in decoupling the mixed selective pressures in coding exons. About 17% of the predicted intronic binding sites are conserved in at least one of the five fish species we analyzed, including those in *UAP1*, Muscleblind-like genes, *PBX1*, *NLGN3*, and others. In contrast, ~19% of the sites are conserved only in mammals. We note that these estimates are biased, due to the artificial enrichment of more conserved sites in our prediction. Nevertheless, they point to evolutionary changes in Fox-1/2 splicing regulation, which may contribute to phenotypic differences across different species, or among different individuals in human populations, as illustrated below.

The first example is a 34-nt exon from *PTB* (exon 11) and *nPTB* (exon 10), which results in frame-shifting and nonsense-mediated mRNA decay (NMD) when skipped, and is critical for expression of full-length functional products from both genes (Fig. 6A,C; Supplemental Fig. S7B); Boutz et al. 2007b). Together with regulation by microRNAs, controlled splicing of this exon through autoregulation switches expression from *PTB* to *nPTB* in developing neurons, which in turn results in reprogramming of the splicing patterns of their target RNAs (Boutz et al. 2007a,b; Makeyev et al. 2007). In addition to these negative regulators, we found that Fox-1/2 strongly activate inclusion of the *nPTB* exon, presumably by interacting with the two DIF sites, D-I and D-II, in contrast, the effect of Fox-1/2 on the paralogous *PTB* exon is more subtle (Fig. 6A). Comparison of the two paralogs revealed

Figure 6. Creation and loss of Fox-1/2-binding sites reflect potential fine-tuning of gene expression after gene duplication. (A) A 34-nt paralogous cassette exon from *PTBP1* (PTB) and *PTBP2* (nPTB). For each gene, the conservation pattern of the region is displayed under the diagram. The two downstream conserved putative Fox-1/2-binding sites (D-I, D-II) are labeled. Results of RT-PCR analysis are shown on the right for each exon. For each panel, the quantified exon inclusion level is indicated. (B) A 36-nt cassette exon from *MBNL1*, *MBNL2*, and *MBNL3*, shown similarly as in A. The *MBNL1* and *MBNL2* exons have two copies of the Fox-1/2-binding site, one in the UIF sequences close to the 3' splice site (U-I) and the other in the exon (E-II). The *MBNL3* exon has an additional site in the UIF sequences (U-III). For each panel, the quantified exon inclusion level is indicated. (C) The presence or absence of Fox-1/2-binding sites in 28 vertebrate species for the sites labeled in A and B. The presence of each site in each species is color-coded and shown under the phylogenetic tree. The BLS for each site is shown on the right. For the *PTB* exon, site D-I appears to be lost in placental mammals by a T-to-C mutation at the first position, resulting in a CGCAUG element, which is shown in green. For the *MBNL3* exon, site U-I is polymorphic in human and overlaps with an A/G SNP (rs3736748) at the fourth position. (D) The allele frequency of the SNP rs3736748 in African Americans (YRI), Europeans (CEU), and Asians (HCB/JPT) was determined according to HapMap data. The A allele (blue) results in an intact Fox-1/2-binding site and the G allele (yellow) results in a disrupted site.

species is color-coded and shown under the phylogenetic tree. The BLS for each site is shown on the right. For the *PTB* exon, site D-I appears to be lost in placental mammals by a T-to-C mutation at the first position, resulting in a CGCAUG element, which is shown in green. For the *MBNL3* exon, site U-I is polymorphic in human and overlaps with an A/G SNP (rs3736748) at the fourth position. (D) The allele frequency of the SNP rs3736748 in African Americans (YRI), Europeans (CEU), and Asians (HCB/JPT) was determined according to HapMap data. The A allele (blue) results in an intact Fox-1/2-binding site and the G allele (yellow) results in a disrupted site.

that *PTB* has a T-to-C substitution at the first position of the proximal D-I site, creating a CGCAUG element with weaker affinity for Fox-1/2 (Fig. 6A,C; Supplemental Fig. S7B). The loss of UGCAUG occurred in the last common ancestor of placental mammals, because an intact UGCAUG element is preserved in four nonmammalian vertebrates. Such a lineage-specific alteration may have contributed to the evolution of PTB SRNs in mammals.

The second example is a 36-nt cassette exon from three Muscleblind-like genes, *MBNL1*, *MBNL2*, and *MBNL3* (Fig. 6B,C; Supplemental Fig. S7C). We predicted and validated all three paralogous exons as Fox-1/2 targets (Fig. 6B,C). In the *MBNL1* and *MBNL2* exons, there are two Fox-1/2-binding sites as putative silencers: one overlapping with the polypyrimidine tract (−14 to −9, denoted as U-I) and the other in the exonic region (12–17, denoted as E-II). Both sites are conserved in almost all vertebrate species we analyzed. Interestingly, the U-I site upstream of the *MBNL3* exon is polymorphic in human populations: It overlaps with an A/G SNP (rs3736748) at the fourth position, resulting in two alleles UGC[A/G]UG, although the site is conserved in most vertebrates. In addition, another site (U-III) was created further upstream from the exon (Fig. 6B; Supplemental Fig. S7C). Interestingly, the allele frequency of the SNP differs radically in different populations, according to HapMap data ($\chi^2 = 153$, $P = 6 \times 10^{-34}$) (The International HapMap Consortium 2007). Consequently, the Fox-1/2-binding site is intact in most Africans (YRI), but is disrupted in most Asians (HCB/JPT), with Europeans (CEU) somewhere in between. We validated by direct sequencing that the U-I site is intact in HeLa cells (African origin), which is consistent with the increased exon skipping upon Fox-1/2 expression. This example provides a good model to study how genetic variations may affect splicing regulation and result in phenotypic differences among individuals.

In these two examples, the paralogous intronic sequences, especially the Fox-1/2-binding sites, can still be aligned, despite considerable nucleotide substitutions. We found more examples belonging to this category, including another exon pair from *MBNL1/2* (Supplemental Fig. S7D), *NLGN3/4X/4Y* (Supplemental Fig. S7E), and *EBP41/41L2* (Supplemental Fig. S7F). However, this is not always the case: In two pairs (or trios), one from Fox-1/2 (Supplemental Fig. S7A) and the other from *ELAVL2/3/4* (Supplemental Fig. S7G), the intronic sequences, including the putative Fox-1/2-binding sites, are very difficult to align. Since the Fox-1/2 sites in each paralog are significantly conserved across vertebrate species, the creation/loss of putative binding sites occurred very early after gene duplication, and was then fixed in the descendent species. Therefore, gene duplication can be followed by splicing divergence, providing parallel paths for producing genetic diversification.

Discussion

Extensiveness of Fox-1/2 SRNs

In this study, we used the highly conserved and related brain-, heart-, and muscle-specific splicing factors Fox-1

and Fox-2 as a model to predict their RNA targets, and to define and characterize their SRNs. By comprehensive phylogenetic analysis of the specific Fox-1/2 motif in 28 vertebrate species, we predicted thousands of target exons and genes with conserved Fox-1/2-binding sites in vertebrates. We estimate by statistical analysis that ~76% of the predicted targets are bona fide targets, and indeed, more than half of a set of 55 predicted targets could be validated experimentally by manipulating Fox-1/2 expression in HeLa cells. The extent of the SRN is comparable with the gene regulatory networks of certain master transcription factors (Massie and Mills 2008), which is surprising, in light of the very limited number of targets of splicing factors identified to date (for review, see Li et al. 2007).

Our predictions may still represent an underestimate, because we focused only on the conserved components of the Fox-1/2 SRNs that can be predicted with high specificity and sensitivity. Many additional binding sites with a relatively low level of conservation might also be functional, as we observed experimentally (data not shown). Moreover, in some extreme cases, a functional Fox-1/2-binding site can be thousands of nucleotides away from the regulated exon (Nakahata and Kawamoto 2005); such targets would have escaped our predictions. Furthermore, our predictions included several splicing factors involved in brain- and/or muscle-specific splicing, such as Fox-1/2, *PTBP1/2* (*PTB/nPTB*), *CUGBP1/2*, *NOVA1*, and *MBNL1/2/3*. Therefore, potential regulation of these splicing factors by Fox-1/2 implies that the Fox-1/2 SRNs are not limited to direct targets, but probably include a large number of indirect targets as well. Our study highlights the importance of tissue-specific splicing in diversifying gene expression regulation.

Mechanisms of Fox-1/2-dependent exon activation and repression

The effect of splicing factors on splicing activation or repression often depends on the location and context of the regulatory sequences they bind. This was reported both for ubiquitous splicing factors, such as SR proteins (Ibrahim et al. 2005) and hnRNPs (Hung et al. 2008), as well as for tissue-specific splicing factors (Ule et al. 2006). Nova-1/2 regulate target exon inclusion and skipping in a predictable way: Downstream intronic binding sites are usually enhancers, whereas upstream and exonic binding sites are usually silencers. A similar mechanism was already proposed for Fox-1/2, based on studies of a few exons, such as *ATP5C1* (*F1 γ*) exon 9, fibronectin EIIIB exon, *c-src* N1 exon, and *EWS* exon 4' (Jin et al. 2003; Underwood et al. 2005). The enhancer character of downstream Fox-1/2 sites was confirmed on a larger scale by several studies focusing on brain- or muscle-specific exons (Sugnet et al. 2004; Das et al. 2007). However, the silencer character of upstream binding sites was not obvious from these studies. Therefore, it was unclear whether there is a general mechanism predictive of Fox-1/2-mediated splicing patterns. Our comprehensive prediction of Fox-1/2 targets, followed by unbiased experi-

mental validation, leads to a conclusive answer: Our analyses of splicing microarrays, and RT-PCR data in primary tissues and in HeLa cells in the presence and absence of Fox-1/2, very consistently demonstrate that downstream intronic Fox-1/2 sites are potent enhancers, whereas upstream intronic sites have the opposite effect.

More experiments are required to understand the underlying mechanisms of how Fox-1/2 interact with the spliceosome to modulate splicing. Putative Fox-1/2-binding sites are generally more enriched in the downstream intron, with a distribution peak ~30 nt from the exon; the upstream intron shows a smaller enrichment with a broader distribution (Yeo et al. 2007; data not shown). Interestingly, for alternative 5' splice sites, putative Fox-1/2-binding sites show a strong preferential location in the DIF region, whereas for alternative 3' splice sites, a more moderate enrichment in the UIF region is seen. The preferential enrichment at particular distances downstream from 5' splice sites suggests that Fox-1/2 might be more efficient at enhancing 5' splice site recognition. In contrast, the mechanisms through which Fox-1/2 block exon recognition might be more heterogeneous. For example, in the context of *hF1 γ* gene exon 9, Fox-1 binding to a GCAUG element in intron 8 blocks prespliceosomal E-complex formation in intron 9, resulting in skipping of exon 9 (Fukumura et al. 2007). We found cases (e.g., exons from Muscleblind-like genes) in which the Fox-1/2-binding sites in the UIF region are very close to the downstream 3' splice site. In these cases, Fox-1/2 likely block the recognition of the intron preceding the alternative exon by interfering with binding of spliceosomal components that recognize the polypyrimidine tract, 3' splice site, and/or branch site. Furthermore, for alternative exons with multiple Fox-1/2-binding sites, these sites are not equivalent in Fox-1/2-dependent activation or repression of exon inclusion. Rather, the sites closer to the splice sites appear to be more efficient than the distal sites, at least with the two minigenes we tested. One interpretation is that Fox-1/2 proteins bound to the proximal sites are more efficient at directly interacting with spliceosomal components.

The potential functional differences between isoforms of Fox-1/2, as well as between the two paralogs, on target recognition and splicing are another interesting question. Fox-2 is reported to autoregulate its expression by repressing the inclusion of exon 6 (Baraniak et al. 2006). Indeed we predicted this exon as a target; in addition, we also predicted four other exons in *Fox-1*, and one other exon in *Fox-2*, as potential targets for autoregulation. Among them are one of the mutually exclusive exons in *Fox-1* and its paralogous exon in *Fox-2* (Supplemental Fig. S7A). The *Fox-1* exon, dubbed B40, is specifically included in brain, whereas the other mutually exclusive exon, M43, is specifically included in muscle (Nakahata and Kawamoto 2005). Therefore, Fox-1/2-mediated AS of these two exons might be important for generating different isoforms of Fox-1/2 proteins in different tissues, which may in turn affect target gene splicing differently.

In terms of the comparison between Fox-1 and Fox-2, they have similarly high expression in brain and heart/

muscle tissues, but Fox-2 is also widely expressed in other tissues. However, because Fox-1 and Fox-2 recognize the same RNA element (Jin et al. 2003; Auweter et al. 2006; Ponthier et al. 2006), it is impossible to distinguish Fox-1/2 targets through their predicted binding sites, as in the present study. Overexpression and knockdown of Fox-1 or Fox-2 individually or together in HeLa cells suggest that these two proteins have very similar effects in activating or repressing predicted targets. We expect that further insights will be gained by identification of the *in vivo* targets of Fox-1 and Fox-2 experimentally in the appropriate tissue types, as well as by determination of the mechanisms of action of these factors.

Complex splicing patterns suggest potential combinatorial regulation

Overexpression and knockdown of Fox-1/2 in HeLa cells, followed by RT-PCR analysis, demonstrated that our predictions of Fox-1/2 targets are amenable to more detailed experimental follow-up. However, the observed validation rate was somewhat lower than our statistical estimate, and it was not always clear why some predictions were validated while the others failed. A possible explanation is that the FDR based on permutations might be overoptimistic, due to some type of bias; alternatively, some predicted Fox-1/2 sites may be present within RNA secondary structures that make them inaccessible to Fox-1/2; yet another likely possibility is that Fox-1/2 alone are not always sufficient to affect the splicing pattern of a bona fide target pre-mRNA.

Both splicing microarray analysis and RT-PCR validations suggest the existence of exons with complex splicing patterns that cannot be explained by Fox-1/2 regulation alone. Although the effect of Fox-1/2 on splicing of these exons is not always observable because of the difficulty in identifying the appropriate tissues or developmental stages, in some cases, the requirement for other cooperating splicing factors in Fox-1/2-mediated splicing regulation is readily apparent. Our argument is based on comparison of splicing patterns between brain and muscle/heart, where Fox-1/2 are highly expressed. Using splicing microarrays, we identified clusters of cassette exons with inconsistent splicing patterns among these tissues, an indication of combinatorial regulation. This difference is especially pronounced for a cluster of DIF site-containing exons, which are predominantly included in muscle, as expected, but mostly skipped in brain. One good example is the *UAP1* exon, with two downstream intronic binding sites, which was also validated by RT-PCR analysis of primary tissues and HeLa cells. Other splicing activators or repressors might be expressed and functional only in brain or heart/muscle, but not in both. A similar argument might hold for HeLa cells, which would help explain the lack of responsiveness of some exons to manipulating Fox-1/2 expression.

A few splicing factors that interact or have the potential to interact with Fox-1/2 have been reported recently. For example, several additional proteins, including

hnRNPs F/H and PTB/nPTB, are responsible for neuron-specific splicing of the *c-src* N1 exon, besides Fox-1/2 (Underwood et al. 2005). The repressive activity of nPTB in such cases could explain why some exons are skipped, despite the presence of downstream Fox-1/2-binding sites as potential enhancers. Alternatively, muscle-specific activators might also be important for the inclusion of these exons in heart and muscle. Recently, one such factor, called sup-12, was identified in *C. elegans* by a genetic screen (Kuroyanagi et al. 2007). sup-12 coordinately regulates tissue-specific splicing of the fibroblast growth factor receptor gene *egl-15*, by binding to a UGUGU element juxtaposed to the fox-1-binding sites. Because this protein shows a very high level of sequence conservation with the mammalian homologs (RBM38 and RBM24), it will be interesting to see if these mammalian proteins function similarly in cooperative splicing regulation with Fox-1/2.

Implications of Fox-1/2 SRNs for neuromuscular functions, disease, and evolution

This study extends previous observations and indicates that modularity may represent a more general feature of tissue-specific SRNs, with coregulated genes sharing similar cellular functions (Ule et al. 2005b). Many of the predicted target genes are known to have important neuromuscular functions, consistent with the exclusive or preferential expression of Fox-1/2 in brain, heart, and muscle tissues. For example, the list includes genes involved in muscle contraction, such as a number of myosin genes, dystrophin (*DMD*), titin (*TTN*), and tropomyosin 1 (*TPM1*). Several splicing factors known to be important for neuronal and/or muscle-specific splicing are also predicted as Fox-1/2 targets. Not surprisingly, disruption of several of our predicted target genes has been implicated in various neuronal disorders, heart disease, and developmental defects. Among them, two neuroligin genes (*NLGN3* and *NLGN4X*) are mutated in patients with X-linked autism and Asperger syndrome (Jain et al. 2003). These two genes, and another paralog, *NLGN2*, have a paralogous cassette exon with a very conserved downstream intronic Fox-1/2-binding site, and show Fox-1/2-dependent splicing. In addition, 15 predicted target genes, including *Fox-1* itself, show sporadic copy-number variations in autistic patients, (The Autism Genome Project Consortium 2007; Sebat et al. 2007; X. Zhao and J. Sebat, pers. comm.). For complex genetic diseases, sporadic mutations can be found in many separate loci that lack apparent functional relationships. Therefore, placing the discrete disease-associated genes into a gene regulatory network can shed light on common pathological mechanisms for these diseases.

On the other hand, splicing regulatory elements, including the Fox-1/2-binding motif, are generally short. Creation and loss of these elements by random mutations can readily occur during evolution. Not all of these mutations would cause genetic diseases. Instead, some

of the mutations might have only moderate effects and can therefore be tolerated. Two examples we examined included *PTB*, in which a site was likely lost in all mammalian species, and *MBNL3*, in which a site was likely lost in Asians, while being preserved in Africans. Although further testing is required, these observations suggest that tissue-specific SRNs might show considerable divergence between mammals and nonmammalian vertebrates, as well as among different human populations.

Materials and methods

Compilation of exons and AS events using splicing graphs

We built a database of classified AS events (dbCASE, <http://rulai.cshl.edu/dbCASE>) using high-quality transcripts (mRNA/EST) and genome alignment (coverage > 85%, identity > 95%), for human, mouse, rat, and other model organisms (Zhang et al. 2007). Exons, introns, and typical types of AS events were detected using splicing graphs. For this study, we used 204,305 human AG-GT internal exons, with annotations of associated AS events.

For each exon, we analyzed exonic sequences and 200-nt UIF/DIF sequences. Multiple alignments of 28 vertebrate species (Miller et al. 2007) were extracted using the maffrag program obtained from the University of California at Santa Cruz (UCSC) genome browser (<http://genome.ucsc.edu>).

For each human AS event, we also tried to identify the orthologous AS event in mouse and rat. This was done by mapping the genomic coordinates of the AS region in mouse or rat to the human genome using the tool liftOver obtained from the UCSC genome browser. For example, for cassette exons, the alternative exons and the two flanking exons were used for the mapping. The mapped coordinates were then compared with the corresponding regions of human AS events.

Evaluation of motif site conservation

We focused on Fox-1/2 targets with UGCAUG present in human, unless explicitly mentioned. A BLS approach (Stark et al. 2007) was adapted to measure Fox-1/2-binding site conservation, using the multiple alignment and phylogenetic tree of 28 vertebrate species (Miller et al. 2007). Briefly, the BLS of each unique Fox-1/2-binding site (in the same alignment columns) is the total branch length of the phylogenetic tree over which the site is conserved, normalized by the total branch length of the tree spanning all species. We allowed no movement of the sites in the assignment of orthologous sites, given the high-specificity and conservation of Fox-1/2-binding sites. However, in some instances, small insertions/deletions interrupt some sites, partly due to artifacts in sequence alignment (e.g., TGCATGG aligned with TGCAT-G); such indels were tolerated. Therefore, our approach is more restrictive than the original approach (Stark et al. 2007), because we sought to trace the history of each individual site.

To determine the significance of motif site conservation, we estimated the null distribution of BLS using 50 random motifs generated by permutations. Random motifs containing CpG or GCAUG were avoided, because CpGs are underrepresented in vertebrate genomes, and the GCAUG element is at least partially functional for Fox-1/2-mediated splicing (Jin et al. 2003). The same analysis was repeated for each of the random motifs and motif sites to calculate BLS scores. We tried different BLS

thresholds from 0 to 1, with steps of 0.01 to determine an appropriate threshold for Fox-1/2 target prediction. For each threshold, a FDR was calculated by the ratio of the average number of sites with a BLS greater than the threshold for random motifs to that for the Fox-1/2 motif.

Experimental validation of predicted Fox-1/2 targets

From the list of predicted targets, we chose to test genes involved in gene expression regulation, such as transcription and RNA processing, and with links to genetic diseases, but others were also selected at random. Human tissue total RNAs were purchased from Clontech. Two shRNAs against human Fox-2 were cloned into the MSCV retroviral vector as described (Dickins et al. 2005). Human Fox-1 cDNA (NM_018723) was cloned into the pWZL-hygro retroviral vector to express Flag-tagged Fox-1 protein.

To generate stable cell pools, HeLa cells were infected with MSCV (expressing the shRNA against Fox-2), or MSCV plus pWZL-hygro (expressing Fox-1 protein) vectors. We replaced the medium 24 h after infection, and 24 h later, infected cells were selected with puromycin ($2 \mu\text{g mL}^{-1}$) for 72 h. In the case of double infection, cells were treated with hygromycin for 96 h after selection with puromycin. The effect of knockdown or overexpression was confirmed by Western blotting using antibodies against human Fox-1 (donated by S. Powers and D. Mu) and Fox-2 (Bethyl Laboratories, Inc.), respectively. Total RNA was extracted from the stable cell pools using Trizol reagent (Invitrogen) and treated with DNase I. Reverse transcription was carried out using SuperScript II reverse transcriptase as described by Invitrogen. Semiquantitative PCR using Taq polymerase was performed by adding $0.1 \mu\text{L}$ of $[\alpha\text{-}^{32}\text{P}]\text{-dCTP}$ to each $25\text{-}\mu\text{L}$ reaction. The PCR reactions were run for 20–25 cycles depending on the abundance of the targets. The products were analyzed on a 6% native polyacrylamide gel. The primer sequences used for validation are shown in Supplemental Table S7.

The *FMNL3* minigene was cloned into the pcDNA3.1 vector. QuickChange PCR mutagenesis was carried out to generate the mutant constructs. Fugene 6 was used for transfection and RT-PCR analysis was done as above. The *PB1* minigene was generated by inserting a PCR fragment containing the cassette exon plus 243-nt UIF and 253-nt DIF sequences, into intron 1 of the human β -globin gene, using BglII and XhoI sites introduced by site-directed mutagenesis.

Splicing microarrays

We identified exons, exon junctions, and AS events in the human genome by mapping RefSeqs, mRNAs, ESTs, and transcripts from patent databases to the genome. For each gene, 60-nt probes and 36-nt probes were optimized to monitor exons and exon junctions, respectively, and printed on Agilent arrays. These arrays were used to monitor 47 diverse human tissues and cell lines in dye-swap replicates (Supplemental Table S3). Gene expression levels were estimated from probes monitoring constitutive exons and junctions. For each AS event, a proportional change of isoform abundances, relative to a reference pool, was then estimated by adapting a previous method (Ule et al. 2005b). More detailed information and data availability will be described elsewhere (J.C. Castle, C. Zhang, J.K. Shah, A.V. Kulkarni, T.A. Cooper, and J.M. Johnson, in prep.). The raw and processed microarray data, as well as additional information, are available at GEO (<http://www.ncbi.nlm.nih.gov/geo>, under accession GSE11863) and on our Web site (http://rulai.cshl.edu/Rosetta_AS_supp/index.html) for download, and in dbCASE in a searchable form.

GO term and OMIM phenotype analyses

The GO term analysis was performed using the online tool DAVID (Dennis et al. 2003). DAVID gives a *P*-value, before and after multiple-test corrections, based on a modified hypergeometric distribution. We used a background set of 15,040 genes, controlling for the conservation level. More specifically, a gene was included in the control gene set if at least one of its exons has a consecutive hexanucleotide with a BLS greater than a specified threshold ($\text{BLS} \geq 0.22$ for UIF and DIF sequences and $\text{BLS} \geq 0.8$ for exonic sequences). The OMIM phenotypes and associated genes were downloaded in December, 2007 (McKusick 1998).

Statistical analysis

Fisher's exact test in the software package R (<http://www.r-project.org>) was used to evaluate the significance of two-by-two contingency tables.

Acknowledgments

We thank Scott Powers and David Mu for providing Fox-1 antibody, John Conboy for critical reading of the manuscript, and Lily Chan for technical help. This work was supported by NIH grant GM74688 (to M.Q.Z. and A.R.K.) and a post-doctoral fellowship from Damon-Runyon Cancer Research Foundation (Z.Z.).

References

- The Autism Genome Project Consortium. 2007. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat. Genet.* **39**: 319–328.
- Auweter, S.D., Fasan, R., Reymond, L., Underwood, J.G., Black, D.L., Pitsch, S., and Allain, F.H.-T. 2006. Molecular basis of RNA recognition by the human alternative splicing factor Fox-1. *EMBO J.* **25**: 163–173.
- Baraniak, A.P., Chen, J.R., and Garcia-Blanco, M.A. 2006. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. *Mol. Cell. Biol.* **26**: 1209–1222.
- Bhalla, K., Phillips, H.A., Crawford, J., McKenzie, O.L.D., Mulley, J.C., Eyre, H., Gardner, A.E., Kremmidiotis, G., and Callen, D.F. 2004. The de novo chromosome 16 translocations of two patients with abnormal phenotypes (mental retardation and epilepsy) disrupt the *A2BP1* gene. *J. Hum. Genet.* **49**: 308–311.
- Black, D.L. 2003. Mechanisms of alternative pre-messenger RNA splicing. *Annu. Rev. Biochem.* **72**: 291–336.
- Blencowe, B.J. 2006. Alternative splicing: New insights from global analyses. *Cell* **126**: 37–47.
- Boutz, P.L., Chawla, G., Stoilov, P., and Black, D.L. 2007a. MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. *Genes & Dev.* **21**: 71–84.
- Boutz, P.L., Stoilov, P., Li, Q., Lin, C.-H., Chawla, G., Ostrow, K., Shiue, L., Ares Jr., M., and Black, D.L. 2007b. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. *Genes & Dev.* **21**: 1636–1652.
- Brudno, M., Gelfand, M.S., Spengler, S., Zorn, M., Dubchak, I., and Conboy, J.G. 2001. Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing. *Nucleic Acids Res.* **29**: 2338–2348.
- Cartegni, L., Chew, S.L., and Krainer, A.R. 2002. Listening to

- silence and understanding nonsense: Exonic mutations that affect splicing. *Nat. Rev. Genet.* **3**: 285–298.
- Das, D., Clark, T.A., Schweitzer, A., Yamamoto, M., Marr, H., Arribere, J., Minovitsky, S., Poliakov, A., Dubchak, I., Blume, J.E., et al. 2007. A correlation with exon expression approach to identify *cis*-regulatory elements for tissue-specific alternative splicing. *Nucleic Acids Res.* **35**: 4845–4857.
- David, C.J. and Manley, J.L. 2008. The search for alternative splicing regulators: New approaches offer a path to a splicing code. *Genes & Dev.* **22**: 279–285.
- Dennis, G., Sherman, B., Hosack, D., Yang, J., Gao, W., Lane, H., and Lempicki, R. 2003. DAVID: Database for annotation, visualization, and integrated discovery. *Genome Biol.* **4**: R60. doi: 10.1186/gb-2003-4-5-p3.
- Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and Lowe, S.W. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nat. Genet.* **37**: 1289–1295.
- Fagnani, M., Barash, Y., Ip, J., Misquitta, C., Pan, Q., Saltzman, A., Shai, O., Lee, L., Rozenhek, A., Mohammad, N., et al. 2007. Functional coordination of alternative splicing in the mammalian central nervous system. *Genome Biol.* **8**: R108. doi: 10.1186/gb-2007-8-6-r108.
- Fukumura, K., Kato, A., Jin, Y., Ideue, T., Hirose, T., Kataoka, N., Fujiwara, T., Sakamoto, H., and Inoue, K. 2007. Tissue-specific splicing regulator Fox-1 induces exon skipping by interfering E complex formation on the downstream intron of human F1 γ gene. *Nucleic Acids Res.* **35**: 5303–5311.
- Huh, G.S. and Hynes, R.O. 1994. Regulation of alternative pre-mRNA splicing by a novel repeated hexanucleotide element. *Genes & Dev.* **8**: 1561–1574.
- Hung, L.-H., Heiner, M., Hui, J., Schreiner, S., Benes, V., and Bindereif, A. 2008. Diverse roles of hnRNP L in mammalian mRNA processing: A combined microarray and RNAi analysis. *RNA* **14**: 284–296.
- Ibrahim, E.C., Schaal, T.D., Hertel, K.J., Reed, R., and Maniatis, T. 2005. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. *Proc. Natl. Acad. Sci.* **102**: 5002–5007.
- The International HapMap Consortium. 2007. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**: 851–861.
- International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome. *Nature* **409**: 860–921.
- Ip, J.Y., Tong, A., Pan, Q., Topp, J.D., Blencowe, B.J., and Lynch, K.W. 2007. Global analysis of alternative splicing during T-cell activation. *RNA* **13**: 563–572.
- Jamain, S. 2003. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat. Genet.* **34**: 27–29.
- Jin, Y., Suzuki, H., Maegawa, S., Endo, H., Sugano, S., Hashimoto, K., Yasuda, K., and Inoue, K. 2003. A vertebrate RNA-binding protein Fox-1 regulates tissue-specific splicing via the pentanucleotide GCAUG. *EMBO J.* **22**: 905–912.
- Johnson, J.M., Castle, J., Garrett-Engle, P., Kan, Z., Loerch, P.M., Armour, C.D., Santos, R., Schadt, E.E., Stoughton, R., and Shoemaker, D.D. 2003. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. *Science* **302**: 2141–2144.
- Kawamoto, S. 1996. Neuron-specific alternative splicing of non-muscle myosin II heavy chain-B pre-mRNA requires a *cis*-acting intron sequence. *J. Biol. Chem.* **271**: 17613–17616.
- Kaynak, B., von Heydebreck, A., Mebus, S., Seelow, D., Hennig, S., Vogel, J., Sperling, H.-P., Pregla, R., Alexi-Meskishvili, V., Hetzer, R., et al. 2003. Genome-wide array analysis of normal and malformed human hearts. *Circulation* **107**: 2467–2474.
- Keene, J.D., Komisarow, J.M., and Friedersdorf, M.B. 2006. RIP-Chip: The isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. *Nat. Protoc.* **1**: 302–307.
- Kiehl, T.-R., Shibata, H., Vo, T., Huynh, D.P., and Pulst, S.-M. 2001. Identification and expression of a mouse ortholog of A2BP1. *Mamm. Genome* **12**: 595–601.
- Kuroyanagi, H., Ohno, G., Mitani, S., and Hagiwara, M. 2007. The Fox-1 family and SUP-12 coordinately regulate tissue-specific alternative splicing in vivo. *Mol. Cell. Biol.* **27**: 8612–8621.
- Li, Q., Lee, J.-A., and Black, D.L. 2007. Neuronal regulation of alternative pre-mRNA splicing. *Nat. Rev. Neurosci.* **8**: 819–831.
- Lim, L.P. and Sharp, P.A. 1998. Alternative splicing of the fibronectin EIIIB exon depends on specific TGCATG repeats. *Mol. Cell. Biol.* **18**: 3900–3906.
- Lopez, A.J. 1998. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation. *Annu. Rev. Genet.* **32**: 279–305.
- López-Bigas, N., Audit, B., Ouzounis, C., Parra, G., and Guigó, R. 2005. Are splicing mutations the most frequent cause of hereditary disease? *FEBS Lett.* **579**: 1900–1903.
- Makeyev, E.V., Zhang, J., Carrasco, M.A., and Maniatis, T. 2007. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. *Mol. Cell* **27**: 435–448.
- Maniatis, T. and Reed, R. 2002. An extensive network of coupling among gene expression machines. *Nature* **416**: 499–506.
- Martin, C., Duvall, J., Ilkin, Y., Simon, J., Arreaza, M., Wilkes, K., Alvarez-Retuerto, A., Whichello, A., Powell, C., Rao, K., et al. 2007. Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **144B**: 869–876.
- Massie, C.E. and Mills, I.G. 2008. ChIPping away at gene regulation. *EMBO Rep.* **9**: 337–343.
- McKee, A., Neretti, N., Carvalho, L., Meyer, C., Fox, E., Brodsky, A., and Silver, P. 2007. Exon expression profiling reveals stimulus-mediated exon use in neural cells. *Genome Biol.* **8**: R159. doi: 10.1186/gb-2007-8-8-r159.
- McKusick, V.A. 1998. *Mendelian inheritance in man. A catalog of human genes and genetic disorders*. Johns Hopkins University Press, Baltimore.
- Meyer, B.J. 2000. Sex in the worm: Counting and compensating X-chromosome dose. *Trends Genet.* **16**: 247–253.
- Miller, W., Rosenbloom, K., Hardison, R.C., Hou, M., Taylor, J., Raney, B., Burhans, R., King, D.C., Baertsch, R., Blankenberg, D., et al. 2007. 28-Way vertebrate alignment and conservation track in the UCSC genome browser. *Genome Res.* **17**: 1797–1808.
- Minovitsky, S., Gee, S.L., Schokrpur, S., Dubchak, I., and Conboy, J.G. 2005. The splicing regulatory element, UGCAUG, is phylogenetically and spatially conserved in introns that flank tissue-specific alternative exons. *Nucleic Acids Res.* **33**: 714–724.
- Moore, M.J. and Silver, P.A. 2008. Global analysis of mRNA splicing. *RNA* **14**: 197–203.
- Nakahata, S. and Kawamoto, S. 2005. Tissue-dependent isoforms of mammalian Fox-1 homologs are associated with tissue-specific splicing activities. *Nucleic Acids Res.* **33**: 2078–2089.

- Norris, J.D., Fan, D., Sherk, A., and McDonnell, D.P. 2002. A negative coregulator for the human ER. *Mol. Endocrinol.* **16**: 459–468.
- Ponthier, J.L., Schluepen, C., Chen, W., Lersch, R.A., Gee, S.L., Hou, V.C., Lo, A.J., Short, S.A., Chasis, J.A., Winkelmann, J.C., et al. 2006. Fox-2 splicing factor binds to a conserved intron motif to promote inclusion of protein 4.1R alternative exon 16. *J. Biol. Chem.* **281**: 12468–12474.
- Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T., Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., et al. 2007. Strong association of de novo copy number mutations with autism. *Science* **316**: 445–449.
- Stark, A., Lin, M.F., Kheradpour, P., Pedersen, J.S., Parts, L., Carlson, J.W., Crosby, M.A., Rasmussen, M.D., Roy, S., Deoras, A.N., et al. 2007. Discovery of functional elements in 12 *Drosophila* genomes using evolutionary signatures. *Nature* **450**: 219–232.
- Sugnet, C., Kent, W., Ares, M.J., and Haussler, D. 2004. Transcriptome and genome conservation of alternative splicing events in humans and mice. *Pac. Symp. Biocomput.* **2004**: 66–77.
- Sugnet, C.W., Srinivasan, K., Clark, T.A., Brien, G., Cline, M.S., Wang, H., Williams, A., Kulp, D., Blume, J.E., Haussler, D., et al. 2006. Unusual intron conservation near tissue-regulated exons found by splicing microarrays. *PLoS Computat. Biol.* **2**: e4. doi: 10.1371/journal.pcbi.0020004.
- Thanaraj, T.A., Stamm, S., Clark, F., Riethoven, J.-J., Le Texier, V., and Muilil, J. 2004. ASD: The alternative splicing database. *Nucleic Acids Res.* **32**: D64–D69. doi: 10.1093/nar/gkh030.
- Ule, J., Jensen, K., Mele, A., and Darnell, R.B. 2005a. CLIP: A method for identifying protein–RNA interaction sites in living cells. *Methods* **37**: 376–386.
- Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J.-S., Cline, M., Wang, H., Clark, T., Fraser, C., Ruggiu, M., et al. 2005b. Nova regulates brain-specific splicing to shape the synapse. *Nat. Genet.* **37**: 844–852.
- Ule, J., Stefani, G., Mele, A., Ruggiu, M., Wang, X., Taneri, B., Gaasterland, T., Blencowe, B.J., and Darnell, R.B. 2006. An RNA map predicting Nova-dependent splicing regulation. *Nature* **444**: 580–586.
- Underwood, J.G., Boutz, P.L., Dougherty, J.D., Stoilov, P., and Black, D.L. 2005. Homologues of the *Caenorhabditis elegans* Fox-1 protein are neuronal splicing regulators in mammals. *Mol. Cell. Biol.* **25**: 10005–10016.
- Voelker, R.B. and Berglund, J.A. 2007. A comprehensive computational characterization of conserved mammalian intronic sequences reveals conserved motifs associated with constitutive and alternative splicing. *Genome Res.* **17**: 1023–1033.
- Yeo, G.W., Van Nostrand, E., Holste, D., Poggio, T., and Burge, C.B. 2005. Identification and analysis of alternative splicing events conserved in human and mouse. *Proc. Natl. Acad. Sci.* **102**: 2850–2855.
- Yeo, G.W., Van Nostrand, E.L., and Liang, T.Y. 2007. Discovery and analysis of evolutionarily conserved intronic splicing regulatory elements. *PLoS Genet.* **3**: e85. doi: 10.1371/journal.pgen.0030085.
- Zhang, C., Hastings, M.L., Krainer, A.R., and Zhang, M.Q. 2007. Dual-specificity splice sites function alternatively as 5' and 3' splice sites. *Proc. Natl. Acad. Sci.* **104**: 15028–15033.

Erratum

Genes & Development 22: 2550–2563 (2008)

Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2

Chaolin Zhang, Zuo Zhang, John Castle, Shuying Sun, Jason Johnson, Adrian R. Krainer, and Michael Q. Zhang

In the above-mentioned paper, the year for the received date was incorrect. The correct received/accepted dates are as follows:

Received June 6, 2008; revised version accepted July 28, 2008.

We apologize for the error.

Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2

Chaolin Zhang, Zuo Zhang, John Castle, et al.

Genes Dev. 2008, **22**:

Access the most recent version at doi:[10.1101/gad.1703108](https://doi.org/10.1101/gad.1703108)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2008/09/16/22.18.2550.DC1>

Related Content

Erratum

[Genes Dev. October , 2008 22: 2902](#)

References

This article cites 59 articles, 23 of which can be accessed free at:

<http://genesdev.cshlp.org/content/22/18/2550.full.html#ref-list-1>

Articles cited in:

<http://genesdev.cshlp.org/content/22/18/2550.full.html#related-urls>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).